OBJECTIVES: In Europe, almost 14% of non–small-cell lung cancer (NSCLC) patients harbor a mutation in the epidermal growth factor receptor gene (EGFR Mut+). Real-world evidence regarding the management and outcomes of these patients is scarce, especially among Caucasian populations. The present study aimed to examine the profile, management, and outcomes of patients with EGFR Mut+ NSCLC in a Greek real-world setting.

METHODS: Data were extracted from a hospital-based registry of patients who took care in the Oncology Unit of “Sotiria” Hospital, in Athens, Greece. Demographic, clinical characteristics, treatment and outcomes for all EGFR Mut+ patients diagnosed from 1/1/2016 and onward were extracted. Outcomes evaluated were the progression-free survival (PFS) and the overall survival (OS).

RESULTS: Of the 292 NSCLC patients, EGFR mutations were detected to 40 (13.7%) of them. The mean (standard deviation) age of EGFR Mut+ patients was 66.8 (13.0) years with 55.0% of them being female and 79.0% diagnosed at stage IV. Brain metastasis at the time of diagnosis was detected in 22.5% of patients. Exon 19 deletion (52.5%) and exon 21 L858R point mutation (22.5%) were identified most frequently. EGFR-TKIs were the most commonly prescribed first-line therapy (78.9%), while 15.8% of patients were treated with chemotherapy and 5.3% with chemotherapy and non-EGFR TKI targeted therapy. The median duration of first line treatment was 11 months and the median (1^st, 3^rd quartile) PFS was 13 (5, 24) months. Among patients receiving second line treatment, 54.5% were treated with EGFR TKIs, as well. Nineteen patients (47.5%) had been also subjected to radiotherapy with the whole brain radio therapy being the most commonly applied one (57.9%). The median OS was not reached.

CONCLUSIONS: This study provides useful insights regarding the management and the outcomes of EGFR Mut+ patients with NSCLC in Greece. Patients recruitment is ongoing in order to obtain more robust results.